Parathyroid Hormone-Related Peptide (PTHrP)
Also known as: PTHrP, PTH-rP, abaloparatide analog, PTHLH gene product
Endogenous paracrine/autocrine peptide hormone; PTH1R agonist; calcium-regulating factor; PTHLH gene product; bone anabolic agent (pharmacological derivatives)
What it is
PTHrP is studied by oncologists and endocrinologists for its central role in cancer-associated hypercalcemia, by bone specialists for its anabolic effects in osteoporosis (as the basis of the drug abaloparatide), and by researchers targeting cartilage repair and bone metastasis. People encountering PTHrP in a clinical context most often hear about it as a tumour marker or a cause of dangerously elevated calcium.
The scientific side
PTHrP (parathyroid hormone-related peptide) is an endogenous polyhormone encoded by the PTHLH gene that shares significant N-terminal sequence homology with parathyroid hormone (PTH), enabling both peptides to bind and activate the same class B G-protein-coupled receptor, PTH type 1 receptor (PTH1R) (PMID 42722652). PTHrP is constitutively expressed in numerous normal tissues — including breast epithelium, keratinocytes, smooth muscle, cartilage, and kidney — where it acts as a local paracrine and autocrine regulator rather than a classical circulating hormone at physiological concentrations. Its endocrine actions become clinically prominent only when tumour cells secrete PTHrP in excess into the systemic circulation, producing humoral hypercalcemia of malignancy (HHM) (PMID 42754527). At PTH1R, PTHrP activates both Gs-cAMP-PKA and Gq-IP3-PKC signalling cascades, driving renal tubular calcium reabsorption, phosphaturia, and stimulation of 1,25-dihydroxyvitamin D synthesis. In bone, PTH1R activation on osteoblasts and osteocytes upregulates RANKL, increasing osteoclast differentiation and bone resorption, releasing calcium and matrix-embedded growth factors; the net calcium flux is responsible for malignancy-associated hypercalcemia (PMID 42373268). A key spatial determinant of PTHrP versus PTH signalling outcomes is receptor trafficking: PTHrP signals predominantly at the plasma membrane, while PTH additionally signals from endosomes after internalisation, producing distinct downstream biological profiles including differing durations of cAMP generation (PMID 42722652). In the growth plate, PTHrP produced by periarticular chondrocytes acts through PTH1R on proliferating chondrocytes to suppress their terminal differentiation and hypertrophy, maintaining the pool of proliferating cells in concert with Indian Hedgehog (Ihh) in a paracrine negative feedback loop; disruption of this axis causes skeletal dysplasias (PMID 42631736, PMID 42630974). In articular cartilage, PTHrP buffers Wnt/beta-catenin activity through a PKC-zeta-dependent negative feedback loop to preserve chondrocyte identity and attenuate osteoarthritis progression (PMID 40735514). During lactation, mammary gland cells secrete PTHrP into maternal circulation to mobilise skeletal calcium stores, driving transient physiological hypercalcemia in susceptible individuals (PMID 23782944). Pharmacological exploitation of PTH1R partial agonism — as seen with abaloparatide, which preferentially drives anabolic bone formation over bone resorption — exploits the conformational selectivity at PTH1R to achieve net bone gain for osteoporosis treatment (PMID 42532988).
Class: Endogenous paracrine/autocrine peptide hormone; PTH1R agonist; calcium-regulating factor; PTHLH gene product; bone anabolic agent (pharmacological derivatives)
Administration & storage
- Administration
- Subcutaneous injection into the periumbilical abdominal region (abaloparatide clinical use)Subcutaneous injection into thigh or upper arm (alternative sites in clinical studies)Local intra-articular delivery in preclinical OA modelsScaffold-incorporated delivery for bone defect repair (preclinical)
- Storage
- Abaloparatide multi-dose pen: refrigerate at 2–8°C (36–46°F) before first use; after first use, may be stored at room temperature (up to 25°C/77°F) for up to 30 days. Do not freeze. Protect from light. Discard used needles and pen after 30 days of use. Research-grade PTHrP peptide fragments: store lyophilised at -20°C or -80°C; reconstituted solutions are typically aliquoted and stored at -20°C to prevent freeze-thaw degradation; use within manufacturer-specified timeframes.
- Cautions
- Contraindicated in patients with elevated baseline risk of osteosarcoma: Paget's disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses (paediatric patients), or prior skeletal irradiation (black box warning on abaloparatide based on rat osteosarcoma carcinogenicity studies; the human relevance of this risk is uncertain but leads to a 2-year lifetime limit on use),Risk of orthostatic hypotension: administer while seated or lying down and keep patient observed for at least 4 hours after injection; clinical trials reported dizziness and postural hypotension as adverse events,Hypercalcaemia and hypercalciuria: monitor serum and urine calcium, particularly in patients with urolithiasis; avoid in patients with active urolithiasis or pre-existing hypercalcemia,Not recommended during pregnancy or lactation: PTHrP physiology is altered during these states; pharmacological PTH1R stimulation carries unknown fetal and neonatal risks,Do not use in patients with metastatic bone disease or active malignancy: pharmacological PTH1R agonism could theoretically stimulate PTHrP-responsive tumour niches or accelerate bone remodelling in metastatic disease
Legal & regulatory status
PTHrP itself is not an approved drug product. However, abaloparatide (Tymlos, Radius Health), a 34-amino-acid synthetic analogue derived from the N-terminal region of human PTHrP(1–34), was approved by the FDA in April…
PTHrP and its analogues, including abaloparatide, are not explicitly listed by name on the current WADA Prohibited List. However, peptide hormones, growth factors, and related substances (WADA category S2) include PTH…
Abaloparatide (Tymlos) received Health Canada approval for postmenopausal osteoporosis with high fracture risk, following the same clinical data package used for FDA approval. Regulatory guidance from Health Canada…
What it's studied for
- Humoral hypercalcemia of malignancy (HHM) — PTHrP as biomarker and pathogenic driver Clinical — multicentre cohort / systematic review
- Osteoporosis — PTHrP(1–34) analogue abaloparatide for bone anabolic therapy and fracture prevention Phase III RCT / FDA-approved indication (abaloparatide)
- Skeletal dysplasias and growth plate disorders — PTHrP signalling axis Preclinical / human genetic studies
- Breast cancer bone metastasis — PTHrP as driver of osteolytic cycle Preclinical / human observational
- Lactation-associated hypercalcemia — PTHrP as physiological calcium mobiliser Human observational / mechanistic studies
- Osteoarthritis and cartilage homeostasis — PTHrP as chondroprotective regulator Preclinical (animal and in vitro) / early translational
- Cancer cachexia — PTHrP-mediated metabolic and pharmacokinetic disruption Preclinical (animal model)
Safety signals
- Osteosarcoma risk (pharmacological PTH1R agonism) — regulatory black box warning
- Hypercalcemia of malignancy — severe, life-threatening when tumour-derived
- Orthostatic hypotension and dizziness — acute injection-site effect
- Hypercalciuria and nephrolithiasis
- Waning anabolic effect (tachyphylaxis) with prolonged PTH1R agonist treatment
- CYP enzyme suppression and chemotherapy toxicity (tumour-derived PTHrP)
- Skeletal dysplasia from genetic loss-of-function (PTHLH mutations)
All studies (10)
Frequently asked
What does it mean if my doctor says my PTHrP is elevated?
An elevated PTHrP level in the blood typically indicates that a tumour somewhere in the body is producing this protein in excess. PTHrP is a major cause of cancer-related high calcium (hypercalcemia of malignancy). Your doctor will investigate which type of cancer may be responsible and will need to treat the high calcium urgently if it is causing symptoms. Elevated PTHrP with suppressed PTH and no identified cancer can sometimes occur in rare benign conditions (such as lactation), but malignancy must be ruled out first.
Is abaloparatide (Tymlos) the same as PTHrP?
Abaloparatide (brand name Tymlos) is a synthetic drug modelled on the first 34 amino acids of human PTHrP, but it is not identical to natural PTHrP. It was engineered to preferentially activate PTH1R in a way that stimulates bone formation more than bone breakdown, making it effective for osteoporosis. Natural PTHrP is an endogenous protein with dozens of tissue functions; abaloparatide is a targeted pharmaceutical analogue approved for osteoporosis treatment in postmenopausal women and men.
Is PTHrP safe to use as a peptide supplement for bone or muscle?
There is no approved or validated protocol for self-administering PTHrP or its fragments outside of medical supervision. The only clinically approved PTHrP-based agent is abaloparatide, which requires a prescription and carries a boxed warning about a potential (though uncertain) risk of osteosarcoma with long-term use in animal studies. No human safety data exist for self-directed use of research-grade PTHrP peptides. Using PTHrP or related peptides without medical guidance and monitoring is not recommended.
Why does PTHrP cause high calcium in cancer patients?
When tumour cells secrete large amounts of PTHrP into the bloodstream, the peptide mimics parathyroid hormone (PTH) and binds to the same receptor (PTH1R) on bone and kidney cells. This causes bones to release calcium into the blood and kidneys to retain calcium instead of excreting it. The result is hypercalcemia — dangerous levels of calcium in the blood — a condition called humoral hypercalcemia of malignancy (HHM). It can cause confusion, weakness, nausea, and heart rhythm problems if severe.
Can PTHrP levels rise during pregnancy or breastfeeding?
Yes. The mammary gland naturally produces and secretes PTHrP into the mother's bloodstream during lactation to help mobilise calcium from the skeleton for milk production. This is a normal physiological process. In most women this does not cause problems, but in rare cases — especially those with pre-existing hypoparathyroidism, vitamin D metabolism disorders, or reduced kidney function — lactation-associated PTHrP secretion can cause elevated blood calcium levels. If you experience symptoms such as excessive thirst, fatigue, or confusion while breastfeeding, speak with your doctor.
Does PTHrP play a role in cartilage or joint health?
Yes, research shows that PTHrP acts as a natural protective signal in cartilage. In growth plates, PTHrP prevents chondrocytes from maturing too quickly, keeping the pool of growing cells active. In adult joints, PTHrP appears to buffer signalling pathways that drive cartilage breakdown in osteoarthritis. Preclinical studies show that enhancing PTHrP signalling in articular cartilage reduces degeneration in animal osteoarthritis models, but no PTHrP-based treatment for joint disease has yet been approved for clinical use in humans.